FILING ANALYSIS · TUESDAY, NOVEMBER 17
INTERPACE BIOSCIENCES, INC. IDXG — 8-K: Results of Operations and Financial Condition
positive
Interpace Biosciences reported Q3 revenue of $10.4 million, an 18% year-over-year increase, with a loss from continuing operations of $1.5 million, and produced Adjusted EBITDA of $2.1 million, or 20% of revenue. The company's thyroid business showed a 7% year-over-year increase in volume and an 18% year-over-year increase in revenue.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →